Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review
View ORCID ProfileHajira Dambha-Miller, Ali Albasri, Sam Hodgson, Christopher R Wilcox, Shareen Khan, Nazrul Islam, Paul Little, Simon J Griffin
doi: https://doi.org/10.1101/2020.05.19.20106856
Hajira Dambha-Miller
1NIHR Academic Clinical Lecturer and GP, Division of Primary Care and Population Health, University of Southampton
MRCGP, PhDAli Albasri
2Clinical Pharmacist and Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford
DPhilSam Hodgson
3NIHR Academic Clinical Fellow, Division of Primary Care and Population Health, University of Southampton
BM BChChristopher R Wilcox
4NIHR Academic Clinical Fellow, Division of Primary Care and Population Health, University of Southampton
MBBChShareen Khan
5Specialist Pharmacist, Oxford University Hospitals NHS Foundation Trust
MPharmNazrul Islam
6Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
7Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
MBBS, PhDPaul Little
8Professor of Primary Care, Division of Primary Care and Population Health, University of Southampton
FMedSciSimon J Griffin
9Professor of General Practice, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge
FMedSci![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Available from authors with reasonable request
Posted May 26, 2020.
Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review
Hajira Dambha-Miller, Ali Albasri, Sam Hodgson, Christopher R Wilcox, Shareen Khan, Nazrul Islam, Paul Little, Simon J Griffin
medRxiv 2020.05.19.20106856; doi: https://doi.org/10.1101/2020.05.19.20106856
Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review
Hajira Dambha-Miller, Ali Albasri, Sam Hodgson, Christopher R Wilcox, Shareen Khan, Nazrul Islam, Paul Little, Simon J Griffin
medRxiv 2020.05.19.20106856; doi: https://doi.org/10.1101/2020.05.19.20106856
Subject Area
Subject Areas
- Addiction Medicine (348)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2644)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12218)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4091)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2654)
- Health Policy (1004)
- Hematology (362)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (434)
- Neurology (3872)
- Nursing (209)
- Nutrition (577)
- Oncology (2025)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6520)
- Radiology and Imaging (1400)
- Respiratory Medicine (871)
- Rheumatology (406)
- Sports Medicine (342)
- Surgery (447)
- Toxicology (53)
- Transplantation (185)
- Urology (165)